Posted by Michael Wonder on 01 Jul 2024
Neurocrine Biosciences announces US FDA accepts new drug applications and grants priority review for crinecerfont for paediatric and adult patients with CAH
1 July 2024 - PDUFA target action dates in late December 2024.
Neurocrine Biosciences today announced the US FDA has accepted its two new drug applications with priority review designations for crinecerfont in the treatment of children, adolescents and adults with classic congenital adrenal hyperplasia.
